ArticleJournal of gastrointestinal oncology2025
Effects of current smoking on treatment outcomes in metastatic and locally advanced pancreatic carcinoma: a retrospective cohort study using the international PURPLE pancreas cancer registry.
Article in Journal of gastrointestinal oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tobacco smoking accounts for 22% of the pancreatic cancer burden in Australia. Smoking may increase therapy-related adverse effects and was associated with shorter survival in the previous analysis of all stages of pancreatic cancer. There is ongoing uncertainty among clinicians regarding the benefits of encouraging smoking cessation in patients with advanced cancer. The objective of this study was to evaluate the association between current smoking and survival outcomes in patients with advanced pancreatic cancer using real-world registry data. Methods: We studied the impact of ongoing smoking on survival among patients with metastatic and locally advanced pancreatic carcinoma in the Pancreatic Cancer: Understanding Routine Practice & Lifting End Results (PURPLE) Translational Registry. Of 1,454 registry patients, 1,047 had the smoking status of current smokers versus non-smokers recorded and were analysed using inverse probability weighting. Predictor variables were age ≥65 years, locally advanced or metastatic disease, liver metastases, gender, Index of Relative Socio-Economic Advantage and Disadvantage (IRSAD) score, Charlson morbidity index, and presence of >3 metastatic sites. The association between smoking and overall survival (OS), cancer-specific survival (CSS), and progression-free survival (PFS) on first-line systemic treatment was calculated using Cox proportional hazards regression. Results: A total of 19.4% of analysed patients were current smokers. Smokers were more likely to be male (P=0.048), be diagnosed at a younger age (P<0.001), and have a lower socioeconomic status (P=0.001). The results failed to show an impact of current smoking on OS [hazard ratio (HR) =0.92, 95% confidence interval (CI): 0.84-1.01, P=0.09], CSS (HR =0.93 95% CI: 0.85-1.02, P=0.13) or PFS (HR =0.98, 95% CI: 0.90-1.16, P=0.72) for locally advanced and metastatic disease patients combined. Conclusions: In this study of survival outcomes, current smoking was not associated with a reduction in OS, CSS, or PFS among patients with incurable pancreatic cancer. This contrasts with the results of previous studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.